← Back to Search

Monoclonal Antibodies

Bevacizumab Plus Ipilimumab Cohort 1 for Melanoma

Phase 1
Waitlist Available
Led By F. Stephen Hodi, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial is testing the safety of a new combination therapy for melanoma and investigating whether it is more effective than current treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine the safety, tolerability and maximum tolerated dosing for the combination of bevacizumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma
Secondary outcome measures
To determine the best overall response rate by standard solid tumor response criteria, disease control rate, time to tumor progression, and duration of response for the combination of bevacizumab plus ipilimumab in this patient population
To perform correlative studies investigating the effects of this combination therapy on antitumor immunity and tumor vasculature

Trial Design

4Treatment groups
Experimental Treatment
Group I: Bevacizumab Plus Ipilimumab Cohort 4Experimental Treatment1 Intervention
12 subjects
Group II: Bevacizumab Plus Ipilimumab Cohort 3Experimental Treatment1 Intervention
12 subjects
Group III: Bevacizumab Plus Ipilimumab Cohort 2Experimental Treatment1 Intervention
17 subects for this cohort
Group IV: Bevacizumab Plus Ipilimumab Cohort 1Experimental Treatment1 Intervention
5 subjects for this cohort
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab Plus Ipilimumab Cohort 1
2009
Completed Phase 1
~50
Bevacizumab Plus Ipilimumab Cohort 2
2009
Completed Phase 1
~50
Bevacizumab Plus Ipilimumab Cohort 3
2009
Completed Phase 1
~50
Bevacizumab Plus Ipilimumab Cohort 4
2009
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,640 Previous Clinical Trials
4,129,418 Total Patients Enrolled
177 Trials studying Melanoma
57,440 Patients Enrolled for Melanoma
Dana-Farber Cancer InstituteLead Sponsor
1,079 Previous Clinical Trials
340,934 Total Patients Enrolled
32 Trials studying Melanoma
2,864 Patients Enrolled for Melanoma
Genentech, Inc.Industry Sponsor
1,541 Previous Clinical Trials
568,097 Total Patients Enrolled
34 Trials studying Melanoma
1,671 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
F. Stephen Hodi, MD 2009. "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00790010.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top